- 1 **Title:** Intravitreal TSG-6 suppresses laser-induced choroidal neovascularization
- 2 by inhibiting CCR2⁺ monocyte recruitment.
- 3 **Short title:** Effect of TSG-6 in choroidal neovascularization

4

- 5 **Authors:** Sang Jin Kim, 1, 2 * Hyun Ju Lee, 3, 4 Ji-Hyun Yun, 2 Jung Hwa Ko, 3, 4 Da
- 6 Ye Choi, 1 Joo Youn Oh3, 4 *
- 7 *SJK and JYO equally contributed to the work.

8

9

Affiliations:

- ¹ Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan
- 11 University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, 135-710,
- 12 Korea.
- ² Samsung Biomedical Research Institute, 50 Irwon-dong, Gangnam-gu, Seoul,
- 14 135-710, Korea.
- ³ Department of Ophthalmology, Seoul National University Hospital, 101 Daehak-
- ro, Jongno-gu, Seoul 110-744, Korea.
- ⁴ Laboratory of Ocular Regenerative Medicine and Immunology, Biomedical
- 18 Research Institute, Seoul National University Hospital, 101 Daehak-ro, Jongno-
- 19 gu, Seoul 110-744, Korea.

20

The authors declare that no competing financial or personal interests exist.

- 1 Supplementary Figure 1. Flow cytometric analysis of retinal cells at day 3
- 2 after laser photocoagulation to Bruch's membrane.
- 3 TSG-6 treatment did not affect the percentage of CCR2⁺CD11b⁺ or
- 4 CCR2⁺CD11c⁺ cells in the retina.

